"The goal of this study is to explore whether activating the immune system can offer a more sustained approach to disease control." -Gregory L. Beatty, MD, PhD, @upenn.edu Perelman School of Medicine
🔗: lfdn.org/unlocking-immunotherapy
#Immune2Cancer #CancerImmunotherapyMonth
youtu.be/c_oLziq_i5I

#CCTG trial spotlight: The SRC8 clinical trial is investigating whether adding #immunotherapy to #chemotherapy improves outcomes for people with metastatic or unresectable high-risk #sarcoma.
#CancerImmunotherapyMonth #SolvingCancerTogether #Immune2Cancer Trial page> buff.ly/D9zUCFO

CCTG trial spotlight:
#CCTG BR36 clinical trial tests ctDNA to identify lung cancer patients who would benefit from chemotherapy added to their #immunotherapy treatment.
Trial page - buff.ly/ZX1XO8d
#SolvingCancerTogether #CancerImmunotherapyMonth #Immune2Cancer

"Ultimately, our aim is to use these findings to refine patient selection in future trials and move toward more personalized treatment approaches for pancreatic cancer.”
- Katie Bever, MD, @jhu.edu
🔗: lfdn.org/unlocking-immunotherapy
#Immune2Cancer #CancerImmunotherapyMonth #ResearchIsFundamental

"For many years, PDAC was considered resistant to immune-based therapies, but we’re now entering a promising era where that assumption is being challenged." -Kevin C. Soares, MD, @mskcme.bsky.social
lfdn.org/unlocking-immunotherapy
#Immune2Cancer #CancerImmunotherapyMonth

🔬 It’s #CancerImmunotherapyMonth!
Barbara Maier's group investigates how the immune system interacts with solid tumors & how to design new therapies to promote solid tumor-targeted responses ➡️ bit.ly/4jK21fK
🎥 Watch their video to find out more about their research 👇
youtu.be/W4nZz0_WYNQ

💜This #CancerImmunotherapyMonth, we are proud to spotlight the cutting-edge Lustgarten-funded projects that are transforming the treatment of #pancreaticcancer.
🔗https://lfdn.org/unlocking-immunotherapy
#ResearchIsFundamental